Related Experiment Video
Updated: Jul 18, 2025
Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model
Published on: May 6, 2020
Biomarkers for osteoarthritis: Current status and future prospects
Ali Mobasheri1, Christian S Thudium2, Anne-Christine Bay-Jensen2
1Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland; Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania; Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging, Université de Liège, Belgium.
Biomarkers show promise for diagnosing and treating osteoarthritis (OA), a common arthritis. Further research is needed to integrate these biomarkers into clinical practice and drug development for better patient outcomes.
Area of Science:
- Rheumatology and Molecular Medicine
- Biomarker Discovery and Validation
Background:
- Osteoarthritis (OA) is a prevalent global condition causing significant pain, disability, and economic burden.
- Current treatment options for OA lack causal efficacy, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To review current research on osteoarthritis biomarkers.
- To explore the potential of biomarkers in clinical practice, drug development, and clinical trials for OA.
Main Methods:
- Literature review of existing studies on OA biomarkers.
- Analysis of the role of soluble biomarkers in clinical settings.
- Examination of biomarker applications in phenotyping, subtyping, and molecular endotyping.
Main Results:
- Soluble biomarkers require further development to meet clinical standards.
- Biomarkers can enhance patient stratification for more effective clinical trials.
- Biomarkers are crucial for evaluating cell-based therapies and developing personalized OA treatments.
Conclusions:
- Biomarkers hold potential for improving OA diagnosis, treatment, and clinical trial design.
- Development of biomarkers as surrogate endpoints could accelerate drug development.
- Biomarkers are key to advancing personalized medicine and clinical care for osteoarthritis patients.
